SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination. U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad's SneakPeek Snap® products in the U.S through 2040. The patent fu ...

Myriad Genetics, Inc. (MYGN) reported an adjusted earnings per share (EPS) of 4 cents per share in the fourth quarter of 2023 versus the year-ago quarter’s loss of 12 cents. The metric surpassed the Zacks Consensus Estimate of 2 cents by 100%.The quarter’s adjustments exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization.The GAAP loss was 36 cents compared with the prior-year quarter’s loss of 52 cents.For the full year, the adjusted loss was 27 cen ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Matt Scalo - Senior Vice President, Investor Relations Paul Diaz - President & Chief Executive Officer Mark Verratti - Chief Commercial Officer Sam Raha - Chief Operating Officer Scott Leffler - Chief Financial Officer Conference Call Participants Andrew Cooper - Raymond James Prashant Kota - Goldman Sachs Jack Meehan - Nephron Research David Westenberg - Piper Sandler Mason Carrico - Steph ...

For the quarter ended December 2023, Myriad Genetics (MYGN) reported revenue of $196.6 million, up 10.6% over the same period last year. EPS came in at $0.04, compared to -$0.12 in the year-ago quarter.The reported revenue represents a surprise of +1.17% over the Zacks Consensus Estimate of $194.33 million. With the consensus EPS estimate being $0.02, the EPS surprise was +100.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to det ...

F E B R U A R Y 2 7 , 2 0 2 4 Fourth Quarter & Full-Year 2023 Earnings ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________ FORM 10-K _______________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |------------------------------------------------------------ ...

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in Japan to study the prognostic and predictive value of molecular residual disease (MRD) testing. The SCRUM-MONSTAR-SCREEN-3 study will use Myriad's ultra-sensitive MRD test, Precise MRD, to monitor circulating tumor DNA (ctDNA) over time in patients diagnosed with a wide arra ...

SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah. Myriad's Precise Tumor Test, which was also offered by IPG as TheraMap®: Solid Tumor, analyzes ...

Yozayo In the field of genetic testing and precision medicine, Myriad Genetics (NASDAQ: NASDAQ:MYGN) is a progressive company, which can be observed in its steady double-digit revenue growth and the upward revision of revenue guidance for the next year. The financial results of the third quarter of 2023 of the company demonstrate a strong year-over-year growth in testing volumes in various segments, such as hereditary cancer, pharmacogenomics, and prenatal testing. This upward trend is not a temporary incre ...

SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial ...